Cargando…
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy
BACKGROUND AND OBJECTIVE: Discontinuation of fingolimod ≥2 months before pregnancy is recommended to minimize potential teratogenicity. The magnitude of MS pregnancy relapse risk, particularly severe relapses, after fingolimod cessation is unclear, as is whether this risk is reduced by pregnancy or...
Autores principales: | Hellwig, Kerstin, Tokic, Marianne, Thiel, Sandra, Hemat, Spalmai, Timmesfeld, Nina, Ciplea, Andrea I., Gold, Ralf, Langer-Gould, Annette M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10202774/ https://www.ncbi.nlm.nih.gov/pubmed/37217309 http://dx.doi.org/10.1212/NXI.0000000000200110 |
Ejemplares similares
-
Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022) -
The German Multiple Sclerosis and Pregnancy Registry: rationale, objective, design, and first results
por: Thiel, Sandra, et al.
Publicado: (2021) -
Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder
por: Ciplea, Andrea Ines, et al.
Publicado: (2020) -
Safety of potential breast milk exposure to IFN-β or glatiramer acetate: One-year infant outcomes
por: Ciplea, Andrea Ines, et al.
Publicado: (2020) -
Multiple Sclerosis Relapses Following Cessation of Fingolimod
por: Malpas, Charles B., et al.
Publicado: (2022)